focus -WSS

focus

author：comprehensive 2025-09-06 03:32:30 - browse：29517

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Cano Health’s bankruptcy is a warning for Medicare Advantage

focus

WSS

340B reform proposal comes out of Senate working group

MultiPlan and major insurers sued for alleged medical price

Unique patient identifier: Experts argue the benefits, pitfalls

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Global cancer cases to surge 77% by 2050, WHO report says

Bird flu outbreak in cows is latest avian flu curveball

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Alkermes shareholders re

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Medicare proposal to cover medical devices draws a mixed reaction

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

State Dept. review finds Biden bears some blame for Afghanistan failures

Adopting new red light myopia treatments may be short

How to save PrEP access — and even expand it

Global cancer cases to surge 77% by 2050, WHO report says

Duchenne breakthrough therapy leaves behind pioneering families

H5N1 bird flu found in pasteurized milk: what we know

hotspot

Cue Health's Covid

What’s missing from the debate over nursing home staff minimums

Bird flu in milk supply is likely coming from asymptomatic cows

What’s missing from the debate over nursing home staff minimums

Updated Covid vaccine has 54% effectiveness, new study suggests

Adopting new red light myopia treatments may be short

entertainment

focus

focus

explore